Moore Capital Management LP Acquires Shares of 425,332 Annexon, Inc. $ANNX

Moore Capital Management LP bought a new position in Annexon, Inc. (NASDAQ:ANNX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 425,332 shares of the company’s stock, valued at approximately $2,429,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. AQR Capital Management LLC grew its stake in Annexon by 122.6% during the first quarter. AQR Capital Management LLC now owns 73,790 shares of the company’s stock valued at $142,000 after acquiring an additional 40,637 shares in the last quarter. Jane Street Group LLC boosted its holdings in shares of Annexon by 8.2% during the 1st quarter. Jane Street Group LLC now owns 99,924 shares of the company’s stock valued at $193,000 after purchasing an additional 7,553 shares during the last quarter. Acadian Asset Management LLC grew its position in shares of Annexon by 31.1% during the first quarter. Acadian Asset Management LLC now owns 203,990 shares of the company’s stock valued at $393,000 after purchasing an additional 48,345 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Annexon by 1.8% in the second quarter. Geode Capital Management LLC now owns 2,284,773 shares of the company’s stock worth $5,484,000 after purchasing an additional 39,763 shares during the last quarter. Finally, American Century Companies Inc. increased its holdings in shares of Annexon by 6.6% in the second quarter. American Century Companies Inc. now owns 211,195 shares of the company’s stock worth $507,000 after purchasing an additional 13,001 shares during the last quarter.

Wall Street Analysts Forecast Growth

ANNX has been the subject of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Annexon in a research note on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and set a $14.00 price objective on shares of Annexon in a report on Monday, July 20th. Wall Street Zen downgraded Annexon from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Needham & Company LLC raised their target price on shares of Annexon from $11.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a research report on Monday, July 13th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $15.33.

Annexon Trading Down 0.6%

ANNX opened at $4.94 on Tuesday. The firm has a market cap of $936.53 million, a P/E ratio of -4.26 and a beta of 1.18. Annexon, Inc. has a 12 month low of $2.03 and a 12 month high of $7.18. The stock has a 50-day moving average of $5.41 and a 200 day moving average of $5.43.

Annexon (NASDAQ:ANNX) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). On average, research analysts forecast that Annexon, Inc. will post -1.01 earnings per share for the current fiscal year.

Annexon Profile

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.